Company intelligence / Profile preview
Cuorips
Hokkaido*, Japancuorips.co.jp ↗
- Ownership
- Private
- Employees
- ~59
- Development stage
- Other
01
Overview
Cuorips has developed an allogeneic iPS cell-derived cardiomyocyte sheet for severe heart failure. In a clinical trial with eight patients, the treatment was shown to be safe and effective in improving symptoms. The company applied for Japanese regulatory approval in April 2025, marking the world’s first such application for an iPS-based regenerative medical product. No major side effects were observed during trials.
- Therapeutic areas
- Cardiovascular
- Modalities
- Induced pluripotent stem cell derived therapyCell therapyRegenerative medicine product
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
Daiichi Sankyo – option right for worldwide commercialization of the technologyOsaka University – foundational research/collaborationStanford University Department of Cardiothoracic Surgery – joint research agreement
Beyond the preview
Go deeper on Cuorips.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cuorips.